PRODUCT LITERATURE

Gemcitabine in advanced non-small cell lung cancer: A phase II study

---

Gemcitabine is an active agent for treatment of advanced nonsmall cell lung cancer (NSCLC). Weekly treatment with singleagent gemcitabine has shown response rates of 20% to 26%. This Phase II trial was conducted to determine the efficacy and safety of 1000 mg/m2 gemcitabine administered weekly for 3 weeks followed by 1 week or rest (28-day cycle). Patients were required to have histologic evidence of NSCLC and advanced disease, a Zbrod’s performance status of 0 to 2, and measurable disease.
No prior therapy was permitted.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Fonkogem

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment